CD3+CD20+ T cells and their roles in human diseases - PubMed
CD3 + CD20 + T cells are a population of CD3 + T cells co-expressing CD20 that make up to ∼3-5% of the CD3 + T-cell compartment in the peripheral blood of human beings. In healthy individuals, CD3 + CD20 + T cells are heterogeneous for contai …
Consensus recommendations on the management of toxicity …
2024年4月18日 · Bispecific antibodies (BsAb) that target CD3 and CD20 represent a new milestone in the treatment of patients with B-cell non-Hodgkin lymphoma. These drugs have demonstrated remarkable single-agent activity in patients with heavily pretreated disease, and 3 drugs have so far received regulatory approvals in various countries.
CD20 × CD3 bispecific antibodies for lymphoma therapy: latest …
2023年8月3日 · Several CD20 × CD3 bsAbs have demonstrated significant anti-B-cell non-Hodgkin lymphoma (NHL) activity by engaging T cells to target CD20 + NHL cells in clinical trials. Mosunetuzumab, epcoritamab and glofitamab have been …
CD20 Marker and Relevance to Lymphoma - Verywell Health
2022年4月19日 · Learn about the CD20 antigen, where it's found, and how it guides the treatment of lymphomas with monoclonal antibodies.
Current Knowledge about CD3+CD20+ T Cells in Patients with …
In healthy individuals, CD3 + CD20 + T cells are heterogeneous in that they contain a lower proportion of CD4 + cells but produce higher levels of IL-17A and/or IFN-γ than CD3 + CD20 − T cells do. Recent studies have shown the pathogenic behavior of CD3 + CD20 + T cells in autoimmune diseases.
CD3+CD20+ T cells and their roles in human diseases
2019年3月1日 · CD3 + CD20 + T cells are a population of CD3 + T cells co-expressing CD20 that make up to ∼3–5% of the CD3 + T-cell compartment in the peripheral blood of human beings. In healthy individuals, CD3 + CD20 + T cells are heterogeneous for containing a lower proportion of CD4 + cells, but produce higher levels of IL-17A and/or IFN-γ than those ...
MBS303, a Novel 2:1 CD20×CD3 Bispecific Antibody, …
2024年11月5日 · MBS303 is a CD20×CD3 T-cell-engaging bispecific antibody that has a novel 2:1 (CD20:CD3) configuration to kill malignant B cells. This dose-escalation phase Ⅰ trial evaluated the safety and efficacy of single-agent MBS303 in …
Mosunetuzumab, a Novel CD20/CD3 Bispecific Antibody, in …
2020年11月5日 · Mosunetuzumab (RG7828; CD20-TDB) is a full-length, fully humanized immunoglobulin G1 (IgG1) bispecific antibody targeting both CD3 (on the surface of T cells) and CD20 (on the surface of B cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells.
B cell depletion therapies in autoimmune disease: advances and ... - Nature
2020年12月15日 · Originally conceived as a method of eliminating cancerous B cells, BCDTs such as those targeting CD20, CD19 and BAFF are now used to treat autoimmune diseases, including systemic lupus...
Anti-CD20/CD3 T cell–dependent bispecific antibody for the
2015年5月13日 · We describe a B cell–targeting anti-CD20/CD3 T cell–dependent bispecific antibody (CD20-TDB), which is a full-length, humanized immunoglobulin G1 molecule with near-native antibody architecture constructed using “knobs-into-holes” technology.
- 某些结果已被删除